Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 99,313 | 71,430 | 86,771 | 67,455 | 59,952 |
| Cost of Goods | 43,595 | 42,498 | 43,111 | 38,477 | 48,881 |
| Gross Profit | 55,718 | 28,932 | 43,660 | 28,978 | 11,071 |
| Operating Expenses | 108,218 | 110,473 | 117,231 | 124,356 | 125,726 |
| Operating Income | -51,905 | -81,043 | -73,460 | -94,901 | -113,774 |
| Other Income | 3,217 | 1,333 | 1,740 | 1,243 | 4,104 |
| Pre-tax Income | -48,688 | -79,710 | -71,720 | -93,658 | -109,670 |
| Income Tax | -1,373 | -665 | 184 | -2,405 | 1,988 |
| Net Income Continuous | -47,315 | -79,045 | -71,904 | -91,253 | -111,658 |
| Net Income | $-47,315 | $-79,045 | $-71,904 | $-91,253 | $-111,658 |
| EPS Basic Total Ops | -0.11 | -0.19 | -0.15 | -0.25 | -0.33 |
| EPS Basic Continuous Ops | -0.11 | -0.19 | -0.15 | -0.25 | -0.33 |
| EPS Diluted Total Ops | -0.11 | -0.19 | -0.15 | -0.25 | -0.33 |
| EPS Diluted Continuous Ops | -0.11 | -0.19 | -0.15 | -0.25 | -0.33 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.19 | -0.18 | -0.25 | -0.33 |
| EBITDA(a) | $-44,036 | $-70,628 | $-62,158 | $-85,094 | $-105,696 |